PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.

Abstract

The central role of Src in tumor progression and metastasis has validated it as an attractive therapeutic target for the treatment of human breast cancer. The aim of this study was to identify potential Src kinase inhibitor, explore its activity, and mechanism of action in human breast cancer. A strategy integrating focused combinatorial library design, virtual screening, chemical synthesis, and high-throughput screening was adopted and a novel 6-hydrazinopurine-based inhibitor of c-Src kinase PH006 was obtained. The kinase enzymatic activities were measured by enzyme-linked immunosorbent assay. The binding mode between PH006 and Src was profiled by surface plasmon resonance approach and molecular simulation. The anti-proliferative activity was evaluated by Sulforhodamin B (SRB) and Colony formation. The anti-invasion and anti-migration activities were assessed by trans-well and wound healing assay. Results indicated that PH006 was an ATP-competitive Src inhibitor, which selectively inhibited c-Src with an IC₅₀ of 0.38 μM among a panel of 14 diverse tyrosine kinases. PH006 potently inhibited c-Src phosphorylation and c-Src-dependent signal transduction, resulting in inhibition of cell proliferation, migration, and invasion in human breast cancer MDA-MB-231 cells. Further study demonstrated that the anti-proliferative activity of PH006 was ascribed to its capability to arrest cells in G1 phase, while its anti-motility activity was related to suppression of MMP2/9 and HGF secretion. Moreover, PH006 exhibited potent activity against tumor growth as well as metastasis of human breast cancer MDA-MB-435 xenograft beard in nude mice, which was accompanied with reduced Src/FAK signaling in tumor tissue. Taken together, PH006 is a novel selective inhibitor of c-Src and possesses potent activity against breast cancer growth and metastasis, which could be potentially developed as a lead candidate against breast cancers with elevated Src tyrosine kinase activity.

• Authors: Jin-gui Ma, He Huang, Si-meng Chen, Yi Chen, Xian-liang Xin, Li-ping Lin, Jian Ding, Hong Liu, Ling-hua Meng
• Journal: Breast cancer research and treatment (Breast Cancer Res Treat) Vol. 130 Issue 1 Pg. 85-96 (Nov 2011) ISSN: 1573-7217 [Electronic] Netherlands
• PMID: 21181437 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• PH006 compound
• Protein Kinase Inhibitors
• Purines
• src-Family Kinases

Topics

• Animals
• Antineoplastic Agents (chemistry, pharmacology, therapeutic use)
• Breast Neoplasms (drug therapy, enzymology, pathology)
• Cell Adhesion (drug effects)
• Cell Cycle (drug effects)
• Cell Line, Tumor
• Cell Movement (drug effects)
• Cell Proliferation (drug effects)
• Female
• Humans
• Mice
• Mice, Inbred BALB C
• Mice, Nude
• Neoplasm Metastasis
• Phosphorylation (drug effects)
• Protein Binding
• Protein Kinase Inhibitors (chemistry, pharmacology, therapeutic use)
• Purines (chemistry, pharmacology)
• Signal Transduction (drug effects)
• Tumor Burden (drug effects)
• Xenograft Model Antitumor Assays
• src-Family Kinases (antagonists & inhibitors)